1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

NAPSR news: J & J and Glaxo (ViiV Healthcare) join forces to develop HIV combo treatment

The new collaborative effort to develop a single tablet for HIV treatment by industry leaders J &J and Glaxo (Viiv Healthcare) could significantly improve the lives of HIV patients, if successful.

 
PRLog - Jun. 18, 2014 - WASHINGTON, D.C. -- Johnson & Johnson has signed a deal with Viiv Healthcare to collaborate on a new single tablet that incorporates two anti viral treatments. The development of this tablet will theoretically spare HIV patients from some harsh side effects associated with current therapies. The combination therapy plan will include J&J's rilpivirine, which prevents HIV from replicating itself in cells, and ViiV's dolutegravir which blocks an enzyme that allows the virus to crack its host's DNA.

If this collaboration on a single tablet is indeed successful – this will without a doubt challenge Gilead Sciences' dominance in the field. Gilead’s Atripla which contains two NRTIs (nucleoside reverse transcriptase inhibitors) EMTRIVA (emtricitabine) and VIREAD (tenofovir disoproxil fumarate) with one NNRTI (non-nucleoside reverse transcriptase inhibitor) SUSTIVA (efavirenz) is currently the leading treatment, pulling in $3.6 billion last year, according to Fierce Biotech.

A single tablet combo could drastically improve the lives of virologically suppressed HIV patients, the companies said. J&J's rilpivirine, a non-NRTI, claims the same replication-blocking capability will spare HIV patients the jarring side effects that may be experienced with other therapies. By also adding in dolutegravir, an integrase inhibitor, this could give HIV patients a more simplified treatment.

ViiV CMO Dr. John Pottage stated "New options that advance current therapies are increasingly important as patients and clinicians consider HIV care over the long term,"

With such industry leaders paving the way for the advancement of beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their product, once approved. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES! Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

1-800-284-1060

www.napsronline.org

--- End ---

Click to Share

Contact Email:
***@napsronline.org Email Verified
Source:NAPSRx
Phone:1-800-284-1060
City/Town:Washington - District of Columbia - United States
Industry:Education, Health
Tags:Education, pharmaceutical sales, cnpr, pharmaceutical sales training, pharmaceutical sales rep
Shortcut:prlog.org/12338290
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share